Nkarta, Inc.

NASDAQ:NKTX

6.64 (USD) • At close July 24, 2024
Bedrijfsnaam Nkarta, Inc.
Symbool NKTX
Munteenheid USD
Prijs 6.64
Beurswaarde 467,904,864
Dividendpercentage 0%
52-weken bereik 1.28 - 16.24
Industrie Biotechnology
Sector Healthcare
CEO Mr. Paul J. Hastings
Website https://www.nkartatx.com

An error occurred while fetching data.

Over Nkarta, Inc.

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface

Vergelijkbare Aandelen

ZimVie Inc. logo

ZimVie Inc.

ZIMV

21.53 USD

iTeos Therapeutics, Inc. logo

iTeos Therapeutics, Inc.

ITOS

16.41 USD

Quanterix Corporation logo

Quanterix Corporation

QTRX

15.33 USD

InnovAge Holding Corp. logo

InnovAge Holding Corp.

INNV

5.97 USD

Atai Life Sciences N.V. logo

Atai Life Sciences N.V.

ATAI

1.51 USD

Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc.

AVIR

3.83 USD

Aurora Cannabis Inc. logo

Aurora Cannabis Inc.

ACB

5.76 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)